A legislative proposal in Tennessee is setting up a potential showdown with CVS Health, forcing the company to consider separating its pharmacy benefit management (PBM) business from its retail pharmacy operations—or potentially exiting the state altogether. The bill, gaining traction in the Tennessee legislature, represents a growing national effort to increase transparency and address concerns about the influence of PBMs on prescription drug costs.
Pharmacy benefit managers act as intermediaries between drug manufacturers, insurance companies, and pharmacies. They negotiate drug prices, process claims, and manage prescription drug benefits for millions of Americans. However, the business model of PBMs has come under increasing scrutiny, with critics alleging a lack of transparency and potential conflicts of interest. CVS Health, a major player in the healthcare landscape, uniquely integrates these functions: it owns approximately 9,000 retail pharmacy locations nationwide, the health insurer Aetna, and the PBM Caremark.
The Tennessee bill specifically prohibits a single entity from simultaneously owning a retail pharmacy and a pharmacy benefit manager. If enacted, CVS Health estimates it could be forced to close over 130 stores across Tennessee, impacting more than 2,000 jobs. This potential disruption highlights the complex interplay between corporate structure and access to healthcare, particularly in a state where many communities already face limited pharmacy options.
The Core of the Conflict: Vertical Integration
The debate centers on the concept of vertical integration within the pharmaceutical supply chain. CVS Health, like other large companies, argues that integrating these different parts of the business allows for greater efficiency and cost savings. However, lawmakers and consumer advocates contend that this integration creates an inherent conflict of interest. Because CVS Health owns both the PBM and the pharmacy, there are concerns that the PBM may favor directing patients to CVS pharmacies, even if other pharmacies offer lower prices.
“The concern is that when one company controls all aspects of the prescription drug process, it can manipulate the system to its own benefit, potentially at the expense of consumers and independent pharmacies,” explains Michael Thompson, a health policy analyst at the University of Tennessee. He notes that the Tennessee bill is part of a broader trend of states attempting to regulate PBMs and increase transparency in drug pricing. The Nashville Scene provides further detail on the bill’s progression through the Tennessee legislature.
National Implications and the FTC Lawsuit
The situation in Tennessee isn’t isolated. Similar legislative efforts are underway in other states, and the Federal Trade Commission (FTC) is similarly taking a closer look at the practices of PBMs. In July 2024, the FTC filed a lawsuit against CVS Health, alleging that the company’s PBM practices have inflated prescription drug costs for millions of Americans. The Boston Globe reported extensively on the FTC’s allegations, which include claims that Caremark steers patients toward more expensive drugs that generate higher rebates for the company.
The outcome of the Tennessee bill and the FTC lawsuit could have significant ramifications for the entire healthcare industry. If other states follow Tennessee’s lead, it could force other large companies with integrated PBM and pharmacy operations to restructure their businesses. This could lead to increased competition among PBMs and potentially lower drug prices for consumers. However, it could also lead to consolidation within the industry and further reduce consumer choice.
Impact on Access to Care in Tennessee
CVS Health has warned that if the Tennessee bill becomes law, it will be forced to close stores, particularly in rural and underserved areas. This raises concerns about access to healthcare for Tennesseans who rely on CVS pharmacies for their prescriptions and other healthcare needs. The potential closure of these pharmacies could exacerbate existing pharmacy deserts, areas where residents have limited access to pharmaceutical services.
According to data from the Tennessee Board of Pharmacy, several counties in the state already have a limited number of pharmacies. Closing more than 130 CVS stores would disproportionately impact these communities, forcing residents to travel longer distances to fill their prescriptions. This is particularly concerning for elderly patients and those with chronic conditions who may have difficulty traveling.
What Happens Next?
The Tennessee bill is currently awaiting a final vote in the state legislature. If passed, it will be sent to the governor for signature. CVS Health has vowed to fight the bill, arguing that it will harm consumers and reduce access to care. The company is also actively lobbying lawmakers in other states to oppose similar legislation.
The FTC lawsuit against CVS Health is expected to take several years to resolve. The outcome of the lawsuit could influence the future of PBM regulation and the structure of the pharmaceutical industry. The case is being closely watched by consumer advocates, healthcare providers, and industry stakeholders alike.
As the debate over PBMs continues, one thing is clear: the current system is facing increasing scrutiny. Lawmakers and regulators are seeking ways to increase transparency, lower drug prices, and ensure that patients have access to affordable and quality healthcare. The situation in Tennessee serves as a microcosm of this larger national conversation, and its outcome could shape the future of the pharmaceutical landscape for years to come.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or financial advice. It is essential to consult with a qualified healthcare professional or financial advisor for any health concerns or financial decisions.
Have your say: What do you think about the role of PBMs in healthcare? Share your thoughts in the comments below.
